A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

NCT02036502 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Carfilzomib

Sponsor

Merck Sharp & Dohme LLC